Free tool
FAERS Monitor: Pamelor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018013 or its brand name (Pamelor, Nortriptyline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,962
Serious
4,261
71% of reports
Hospitalization
1,488
Death reported
757
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective884
- off label use838
- pain742
- headache733
- fatigue633
- nausea605
- hyperhidrosis594
- hypersensitivity505
- drug hypersensitivity448
- constipation441
- hypertension439
- rheumatoid arthritis423
- hepatic enzyme increased422
- overdose410
- joint swelling403
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 83 |
| 2005 | 83 |
| 2006 | 73 |
| 2007 | 80 |
| 2008 | 70 |
| 2009 | 81 |
| 2010 | 196 |
| 2011 | 197 |
| 2012 | 177 |
| 2013 | 121 |
| 2014 | 155 |
| 2015 | 193 |
| 2016 | 262 |
| 2017 | 236 |
| 2018 | 271 |
| 2019 | 408 |
| 2020 | 422 |
| 2021 | 414 |
| 2022 | 418 |
| 2023 | 453 |
| 2024 | 582 |
| 2025 | 543 |
| 2026 | 444 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,197 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic enzyme increasedSignal | 422 | 22.0 | 20.0 | 8,399 |
| hyperhidrosisSignal | 594 | 16.3 | 15.1 | 8,551 |
| rheumatoid arthritisSignal | 423 | 13.2 | 12.0 | 4,761 |
| joint swellingSignal | 403 | 11.8 | 10.7 | 3,988 |
| hypersensitivitySignal | 505 | 9.6 | 8.8 | 3,916 |
| drug hypersensitivitySignal | 448 | 8.2 | 7.5 | 2,837 |
| hypertensionSignal | 439 | 7.3 | 6.7 | 2,411 |
| constipationSignal | 441 | 7.1 | 6.5 | 2,345 |
| overdoseSignal | 410 | 6.7 | 6.1 | 2,006 |
| painSignal | 742 | 4.3 | 4.0 | 1,905 |
| headacheSignal | 733 | 4.1 | 3.9 | 1,786 |
| off label useSignal | 838 | 3.4 | 3.2 | 1,460 |
| fatigueSignal | 633 | 2.9 | 2.7 | 798 |
| nauseaSignal | 605 | 2.7 | 2.5 | 670 |
| drug ineffectiveSignal | 884 | 2.4 | 2.2 | 743 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.